Phase 1/2 trial of pemetrexed and cisplatin with concurrent thoracic radiation for stage III inoperable nonsquamous non-small cell lung cancer

Phase 1/2 trial of pemetrexed and cisplatin with concurrent thoracic radiation for stage III inoperable nonsquamous non-small cell lung cancer - Phase 1/2 trial of pemetrexed and cisplatin with concurrent thoracic radiation for stage III inoperable

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003632

Enrollment

Registered

2010-06-01

Start date

2010-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non small cell lung cancer

Interventions

Pemetrexed, Cisplatin, Radiotherapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Pathologically confirmed non-squamous non-small cell lung cancer 2)Unresectable stage 3A or3B 3)No previous treatment 4)An age of 20-70 years 5)ECOG performance status (PS) of 0 or 1 6)A life expectancy of 3 months or longer 7)Adequate organ function 8)Written informed consent

Exclusion criteria

Exclusion criteria: 1)Active systemic infection 2)Pregnancy or lactation 3)Ascitic fluid or pleural effusion 4)Pericardial fluid retention 5)Peripheral neuropathy

Design outcomes

Primary

Measure	Time frame
Phase 1:Dose Limiting Toxicity, Maximum Tolerated Dose Phase 2:Response rate	—

Secondary

Measure	Time frame
Phase 1:Response rate Phase 2:Toxicity, Median survival time	—

Countries

Japan

Contacts

Public ContactYoshinobu Iwasaki

Kyoto Prefectural University of Medicine Department of Pulmonary Medicine

yiwasaki@koto.kpu-m.ac.jp075-251-5513

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026